|  |

|

Depression Research Studies

TRIADE – Antidepressant Clinical Trial

Date: Oct. 6, 2011

The TRIADE trial is designed to assess amitifadine, a new drug being developed as a possible new antidepressant intended to reduce many of the side effects associated with typical antidepressant medications.

Who Can Participate in TRIADE?

• People who have major depressive disorder
• People who have not responded adequately to a single course of a previous antidepressant medication (SSRIs or SNRIs)

What is amitifadine?

• Amitifadine is an investigational medication to treat depression that acts on three chemicals in the brain

What can you expect if you participate in TRIADE?

• TRIADE is a 13 week trial
• The purpose of the study is to assess the safety and effectiveness of the investigational medication
• Some participants will be given amitifadine, while some will get a standard treatment and some will be given a pill with no medication (a placebo) for comparison

The trial will be conducted at approximately 30 centers throughout the U.S., and is expected to include approximately 318 individuals.

For full enrollment criteria and to locate a center near you, please call 1 (888) 414-1808 or visit www.trialreach.com/premium/depression.

TRIADE is sponsored by Euthymics® Bioscience, Inc., maker of amitifadine.

Depression/Anxiety Support Group Preferences

Principal Investigator: Amanda E. Brody, MA

We are psychology researchers at the University of Arizona, and we are studying how support groups for depression and anxiety help people.  We would like to invite you to take a brief research survey online.  You DO NOT need to have personally attended a support group in order to participate.

If you are currently experiencing some feelings of depression and/or anxiety and you are 18 or older, you may click the link below to access the survey, which takes up to 20 minutes to complete.  You will not be asked for any information that could identify you during the survey.  Thank you for contributing to research on depression and anxiety!

http://www.surveymonkey.com/s/arizonasupportgroupsurvey

---

The Mind Body Program at Emory University is now recruiting for an NIH-funded project on Treatment Resistant Depression entitled:

An Evaluation of the Efficacy of the Tumor Necrosis Factor-Alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators

Location: Georgia
Age: 25-60

This is a preliminary evaluation to determine whether Infliximab (Remicade) holds promise as a therapeutic intervention for treatment resistant depression.  Infliximab is FDA approved to treat two illnesses: rheumatoid arthritis and Crohn’s disease. Infliximab is thought to help these conditions because it reduces inflammation in the body. People with major depression who have failed approved antidepressants may be especially likely to have increased inflammation as manifested by cytokines such as tumor necrosis factor (TNF)-alpha. For this reason, researchers think that a drug like Infliximab, which blocks TNF-alpha, may be helpful in treating depression.

General Criteria:

• Males or females, ages 25-60
• Current diagnosis: Major Depressive Disorder (HDRS score ≥20) or Bipolar II Disorder (depression episode only)
• Treatment resistant depression: treatment resistance or intolerance ( MGH-S score ≥ 2)
• Medically healthy-without autoimmune disorder
• Have no history of latent or active TB c-reactive protein (CRP) blood level of ≥ 3 (indicative of inflammation)
• Men and women of childbearing potential must use adequate birth control measures
• Free of medication or on a fixed antidepressant regimen for ≥4 weeks prior to   Study week 0. Subjects and their primary care providers must agree to maintain    this dose until the 12-week assessment is complete.

For more information or to make a referral, please contact:

Bobbi Woolwine, MSW, LCSW
Director, Research Projects
404-727-8229; bwoolwi@emory.edu

Posted: April 15, 2009

 

 Read More About Research

|  |

|

---

Join NAMI today!

When you become a member of NAMI, you become part of America's largest grassroots organization dedicated to improving the lives of persons living with serious mental illness. And now you can join online.